BerGenBio ASA, a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce that a member of the senior management team will be presenting at the following virtual conferences:
September 1, 2020
· 4 min read